The Trump administration's overhaul of the federal workforce has left thousands without jobs. Many of those workers have visited the capital since the spring to explain to members of Congress why the firings are wrong and some decided to bring their kids along for what they're calling camp democracy. The Washington Post reports the camp was born to both introduce their kids to the democratic process and provide those in power with an opportunity to learn about the ripple effects of the slash and burn cuts.J ...

The Trump administration's overhaul of the federal workforce has left thousands without jobs. Many of those workers have visited the capital since the spring to explain to members of Congress why the firings are wrong and some decided to bring their kids along for what they're calling camp democracy. The Washington Post reports the camp was born to both introduce their kids to the democratic process and provide those in power with an opportunity to learn about the ripple effects of the slash and burn cuts. ...

From @WSJopinion: Before senators decide to cut funds for global health programs, they should understand what this spending is, what it isn’t, and all the U.S. has gained from it, writes @BillGates https://t.co/XCHfJC5G5D ...

Instead of celebrating a landmark HIV prevention drug, aid groups are scrambling to keep those already infected alive after Trump's gutting of the global health infrastructure, @lisamjarvis says (via @opinion) https://t.co/SGDWStQrGQ ...

Company Overview - DRC Medicine Ltd. is an innovative healthcare and biotechnology company based in Tokyo, Japan, focusing on advanced medical technologies to address global health challenges [3][10] - The company is known for its proprietary Hydro Silver Titanium® technology, which is being developed into therapeutic masks for seasonal allergic rhinitis and a pipeline of In Vitro Diagnostic (IVD) kits for infectious diseases and allergen detection [3][10] - DRC Medicine is also negotiating to acquire an innovative ATP-enhancing drug for Parkinson's disease, currently in clinical trials [3][10] Business Combination Agreement - DRC Medicine has entered into a business combination agreement with Ribbon Acquisition Corp., a special purpose acquisition company, which will lead to DRC becoming publicly traded [2][4] - The proposed transaction implies a pre-money equity value of approximately $350 million for DRC on a fully diluted basis and is expected to provide around $50 million in cash from Ribbon's IPO proceeds [6][8] - Current shareholders of DRC Medicine will retain 100% of their equity and will own approximately 82.91% of the combined company on a pro forma basis, assuming no redemptions by Ribbon's shareholders [6][8] Strategic Focus and Market Trends - The company aims to invest in more IVD kits paired with AI-powered applications to enhance universal diagnostics, addressing the rising demand for better respiratory protection and faster, more accurate IVD kits [4] - DRC's management believes that the growth of airborne allergens, respiratory diseases, and infectious diseases presents significant market opportunities [4] - The combined company is expected to leverage its experienced management team and technology specialists to innovate and expand its healthcare and biotechnology applications in the global market [4]